The lawsuit filed Monday in Cook County Circuit Court states the city has paid nearly $9.5 million for filling opioid prescriptions since 2007. It alleges the pharmaceutical companies' marketing of opioids for long-term use to treat non-cancer pain was false, misleading and "unsupported by science."
Two California counties have filed a lawsuit accusing five drug companies of waging a campaign...
The South Carolina Court of Common Pleas, Fifth Judicial Circuit has issued a ruling that will...
Mylan Inc. today announced that its subsidiary Mylan Pharmaceuticals has received final approval...
Mylan Inc. today announced that its subsidiary, Mylan Pharmaceuticals Inc., has filed suit against the U.S. Food and Drug Administration (FDA) in the U.S. District Court for the District of Columbia seeking to overturn a decision by FDA, which awarded Teva sole 180-day exclusivity for the generic version of its affiliate Cephalon's Provigil.
Teva announced that it has now received all regulatory approvals required to complete its planned purchase of Cephalon after the European Commission cleared the transaction.
Teva Pharmaceutical Industries Ltd. and Cephalon, Inc. announced today that, as expected, each party has received a request for additional information (commonly referred to as a "second request") from the U.S. Federal Trade Commission (FTC) in connection with Teva's pending acquisition of Cephalon.
NEW YORK (AP) — Teva Pharmaceutical Industries Ltd. has agreed to buy Cephalon Inc. for $6.8 billion in a deal that would give the world's largest generic drug developer a range of biotechnology drugs aimed at cancer and other conditions
Cephalon, Inc. has announced that its wholly-owned subsidiary, Cephalon CXS Holdings Pty Ltd (Cephalon), has lodged the offer document (Bidder's Statement) for its A$0.70 a share offer for ChemGenex Pharmaceuticals Limited (ASX: CXS) (ChemGenex) with the Australian Securities and Investments Commission.
Cephalon Inc.'s shares fell slightly in pre-market trading a day after the U.S. drug company formally rejected a hostile takeover bid by Canada's Valeant Pharmaceuticals International.
Cephalon, Inc. announced that today the United States District Court in Delaware upheld the validity of Cephalon's U.S. Patent Number 6,264,981 patent and found that Watson Pharmaceuticals, Inc.'s proposed generic version of FENTORA® (fentanyl buccal tablet) infringes that patent.
Cephalon, Inc. has signed a definitive merger agreement under which it will acquire all of the outstanding capital stock of Gemin X Pharmaceuticals, Inc., a privately-held biopharmaceutical company developing first-in-class cancer therapeutics, for $225 million cash on a cash-free, debt-free basis.
NEW YORK (AP) — A federal court overturned two of the patents on Cephalon Inc.'s painkiller Fentora, according to Cephalon and Watson Pharmaceuticals Inc., which is challenging the patents.
Cephalon, Inc. and Alba Therapeutics Corporation, a privately held biopharmaceutical company, today announced that the companies have signed an agreement providing Cephalon with an option to purchase all of Alba's assets relating to larazotide acetate, a tight junction modulator, progressing toward a Phase IIb clinical trial for the treatment of celiac disease.
Cephalon, Inc. announced today that its Board of Directors has appointed J. Kevin Buchi as Chief Executive Officer and a member of the company's Board. The Board will address the role of company Chairman in the future. William P. Egan will continue to serve as Cephalon's independent Presiding Director.
NEW YORK (AP) — A federal judge has recommended Watson Pharmaceuticals CEO Paul Bisaro testify in a federal investigation into the generic drug developer's patent settlement with biotechnology company Cephalon.
Cephalon, Inc. has received a Complete Response letter from the FDA for its supplemental new drug application for NUVIGIL® (armodafinil) Tablets [C-IV] in the treatment of patients with excessive sleepiness associated with jet lag disorder resulting from eastbound travel.
Cephalon, Inc. announced today that it has exercised its option to acquire Ception Therapeutics, Inc., following receipt of positive data from a clinical study in adults with eosinophilic asthma.
FRAZER, Pa. (AP) — Biotechnology company Cephalon Inc. said Thursday its fourth-quarter profit surged on a boost in sales and lower charges.
BioClinica, Inc., a global provider of clinical trial services, has signed a three-year, multi-million dollar deal with Cephalon, Inc. for clinical trial technology and support services.
Cephalon, Inc., has announced the promotion of three executives, Kevin Buchi, Wilco Groenhuysen and Alain Aragues.
MATTHEW PERRONE AP Business Writer WASHINGTON (AP) — Federal health regulators have issued enforcement letters to Eli Lilly, Bayer, Amylin Pharmaceuticals and Cephalon for making inaccurate or incomplete statements while promoting their drugs.
Mylan Inc.today confirmed that it was sued by Cephalon Inc. and Cephalon France inconnection with the filing of an Abbreviated New Drug Application (ANDA) withthe U.S. Food and Drug Administration (FDA) for Armodafinil Tablets, 50 mg,150 mg and 250 mg.
Cephalon Executive Vice President of Worldwide Pharmaceutical OperationsRobert Roche to Resign PositionJanuary 8, 2010 4:27 am | News | Comments
Cephalon, Inc., today announced that effective February 5, 2010, Robert P. Roche, Jr.,Executive Vice President of Worldwide Pharmaceutical Operations, will resignhis position with the company to pursue other longstanding interests. Duringhis tenure, Mr.
FRAZER, Pa. (AP) — The FDA needs more time to review Cephalon Inc.'s drug Nuvigil as a treatment for jet lag, Cephalon recently announced. Cephalon is seeking approval to market Nuvigil for the treatment of tiredness in jetlagged patients.
Cephalon, Inc. has filed a lawsuit in U.S. District Court in Delaware against Teva Pharmaceuticals USA, Inc. for infringement of U.S. Patent Nos.
GENE JOHNSON Associated Press Writer SEATTLE (AP) — Seattle biotechnology firm Cell Therapeutics Inc. can pursue claims for nearly $23 million against a former consultant, a federal appeals court ruled Wednesday. The ruling by a three-judge panel of the 9th U.S.
NEW YORK (AP) — Cephalon Inc. will give Barr Pharmaceuticals Inc. a license to sell a generic version of the pain drug Fentora in 2018 as part of a patent lawsuit settlement, according to a Securities and Exchange Commission filing Thursday.
Cephalon, Inc. and BioAssets Development Corporation, aprivately held biopharmaceutical company, today announced that the companieshave signed an agreement that will provide Cephalon with an option to acquireBDC.
- Page 1